Are current cancer drugs targeted at the wrong kinds of cells? A pioneering approach to the development of treatments uses a mathematical model to follow how different types of tumour cells respond to therapy.
References
Michor, F. et al. Nature 435, 1267–1270 (2005).
Huntly, B. J. & Gilliland, D. G. Nature Rev. Cancer 5, 311–321 (2005).
Bonnet, D. & Dick, J. E. Nature Med. 3, 730–737 (1997).
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).
Singh, S. K. et al. Nature 432, 396–401 (2004).
Sawyers, C. L. et al. Blood 99, 3530–3539 (2002).
Talpaz, M. et al. Blood 99, 1928–1937 (2002).
Hughes, T. & Branford, S. Semin. Hematol. 40, 62–68 (2003).
Gorre, M. E. & Sawyers, C. L. Curr. Opin. Hematol. 9, 303–307 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huntly, B., Gilliland, D. Summing up cancer stem cells. Nature 435, 1169–1170 (2005). https://doi.org/10.1038/4351169a
Published:
Issue Date:
DOI: https://doi.org/10.1038/4351169a
- Springer Nature Limited
This article is cited by
-
Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors
Journal of Ovarian Research (2018)
-
The cilia-regulated proteasome and its role in the development of ciliopathies and cancer
Cilia (2016)
-
Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines
Journal of Experimental & Clinical Cancer Research (2015)
-
A 3D multiscale model of cancer stem cell in tumor development
BMC Systems Biology (2013)
-
HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias
Oncogene (2013)